Your session is about to expire
← Back to Search
(18F)-FEPPA PET/MRI Imaging for Frontotemporal Dementia
N/A
Recruiting
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subject is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal, surgically sterile or practicing an effective form of family planning
Patients diagnosed with a probable Frontotemporal Dementia or neurologically healthy control participants with no history of neurological problems
Must not have
Any significant neurologic disease other than suspected Frontotemporal Dementia that would better account for symptoms (i.e. frontal lobe stroke)
Exclusion Criteria for controls undergoing arterial line placement: Absent pulse, Thromboangiitis obliterans (Buerger disease), Burns over the cannulation site, Inadequate circulation to the extremity, Raynaud syndrome, Anticoagulation therapy, Atherosclerosis of upper extremity vessels, Coagulopathy, inadequate collateral flow, Infection at the cannulation site, Previous surgery in the area, Synthetic vascular graft
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
This trial will use hybrid PET/MRI imaging to study neuroinflammation in frontotemporal dementia patients and its relationship to cerebral perfusion.
Who is the study for?
This trial is for individuals diagnosed with probable Frontotemporal Dementia or healthy controls without neurological issues. Participants need a study partner, must be in good health not affecting the study, and women should not be pregnant or of childbearing potential unless properly managed. Exclusions include significant systemic illness, certain medical conditions that affect MRI safety, other major neurologic diseases besides FTD, recent psychiatric disorders, and those exceeding radiation exposure limits.
What is being tested?
(18F)-FEPPA PET/MRI imaging is being tested to assess neuroinflammation's role in Frontotemporal Dementia (FTD). The trial involves cognitive assessments and advanced imaging techniques to explore the relationship between brain inflammation, blood flow, and brain structure in patients with different subtypes of FTD.
What are the potential side effects?
While the document does not specify side effects related to FEPPA directly since it's an imaging agent used for PET scans; generally such procedures may involve risks from radiation exposure although within safe limits set by health regulations. There might also be discomfort associated with positioning during scanning.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am not pregnant, breastfeeding, and cannot become pregnant.
Select...
I have been diagnosed with probable Frontotemporal Dementia or I am neurologically healthy with no history of neurological issues.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My symptoms are not due to a major neurological condition other than possible Frontotemporal Dementia.
Select...
I do not have conditions like absent pulse, specific vessel diseases, burns, poor circulation, or infections that would prevent arterial line placement.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
1Treatment groups
Experimental Treatment
Group I: (18F)-FEPPAExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Lawson Health Research InstituteLead Sponsor
672 Previous Clinical Trials
414,471 Total Patients Enrolled
5 Trials studying Frontotemporal Dementia
1,211 Patients Enrolled for Frontotemporal Dementia
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have received a high amount of radiation from medical procedures in the past year, exceeding the allowed limit set by Health Canada.My symptoms are not due to a major neurological condition other than possible Frontotemporal Dementia.You have been diagnosed with schizophrenia according to specific criteria.You have important issues with your B12 levels or thyroid function that could affect the study.I can see and hear well enough for brain function tests.You have evidence of infection or other focal lesions on your brain MRI scans.I do not have any major illnesses that would prevent me from following the study's requirements.I do not have conditions like absent pulse, specific vessel diseases, burns, poor circulation, or infections that would prevent arterial line placement.I am willing to join a year-long imaging study.I can have an MRI and PET scan and have no health issues preventing them.I haven't taken any experimental drugs in the last month.You have had severe depression or bipolar disorder in the past year, or you have experienced psychotic features, agitation, or behavior issues in the last 3 months that could make it hard to follow the study rules.I am not pregnant, breastfeeding, and cannot become pregnant.I have been diagnosed with probable Frontotemporal Dementia or I am neurologically healthy with no history of neurological issues.I am in good health with no conditions that could affect the study.
Research Study Groups:
This trial has the following groups:- Group 1: (18F)-FEPPA
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger